Flagship-founded companies joined other leaders in #cellandgenetherapy at the @ASGCTherapy's Annual Meeting, sharing strides in the development of their respective bioplatform technologies and progress toward potentially transformative medicines. Read the full summary and highlights below: bit.ly/3WIUvtp 🔷 @ring_tx shared data in nonhuman primates showing the ability to redose genetic medicines using their vectors based on a little-known class of viruses called anelloviruses. 🔷 @TesseraTx displayed curative results in humanized mouse models using its Gene Writers and proprietary lipid nanoparticles to restore normal hemoglobin production in hematopoietic stem cells in the bone marrow without chemotherapy or mobilization for the treatment of #sicklecelldisease. 🔷 @alltrna demonstrated robust ability to readthrough premature stop codons in mouse models, promising preclinical results that suggest their engineered tRNAs could offer a versatile approach to rescue protein production in rare and ulta-rare diseases caused by nonsense mutations, known as stop codon disease. 🔷 @OmegaTX showed preclinical data highlighting their ability to program epigenetic controllers to upregulate gene expression for a variety of genes types and cell conditions, providing effects that last weeks to months after a single dose. 🔷 Sana Biotechnology displayed data showing a promising safety profile for their in vivo CAR T therapy, suggesting its potential to offer comparable efficacy and genomic safety as established treatments.

Hear from the CEOs and leaders of #FlagshipFounded companies as they share the latest platform & pipeline updates, the therapeutic areas they’re focused on, new & expanded partnerships, how they’re building company culture, and what’s ahead for 2024. Watch all the latest CEO Chats here: bit.ly/48LWm3t #FlagshipJPM #JPM24

Flagship Founder & CEO @NoubarAfeyan shares career shaping experiences and how Flagship and its companies are transforming biotech to improve human health in this @barronsonline Q&A. @blalpert ow.ly/FuUt50Gs2aj @endlessRNA @moderna_tx @OmegaTX @ring_tx @TesseraTx

Flagship-founded @OmegaTX -- pioneering the field of epigenomic programming to precisely regulate and control the epigenetics of the human genome -- has nominated its first development candidate in an historically undruggable target of oncology. #JPM2021 #biotechmoment